Country: Canada
Language: English
Source: Health Canada
ACYCLOVIR
APOTEX INC
J05AB01
ACYCLOVIR
400MG
TABLET
ACYCLOVIR 400MG
ORAL
100
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0115506004; AHFS:
APPROVED
1997-08-21
_____________________________________________________________________________________ _APO-ACYCLOVIR Product Monograph _ _ _ _Page 1 of 39_ PRODUCT MONOGRAPH PR APO-ACYCLOVIR ACYCLOVIR TABLETS APOTEX STANDARD 200 MG, 400 MG AND 800 MG ANTIVIRAL AGENT APOTEX INC. DATE OF PREPARATION: 150 SIGNET DRIVE April 10, 1997 TORONTO, ONTARIO DATE OF REVISION: M9L 1T9 August 31, 2021 Control No. 255331 _____________________________________________________________________________________ _APO-ACYCLOVIR Tablets Product Monograph _ _Page 2 of 39_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................................................. 3 SUMMARY PRODUCT INFORMATION .............................................................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................................................... 3 CONTRAINDICATIONS ......................................................................................................................................... 4 WARNINGS AND PRECAUTIONS ........................................................................................................................ 4 ADVERSE REACTIONS ......................................................................................................................................... 6 DRUG INTERACTIONS .......................................................................................................................................... 9 DOSAGE AND ADMINISTRATION ...................................................................................................................... 9 OVERDOSAGE ...................................................................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY .................................................................................................. Read the complete document